Article Text

Download PDFPDF
A case of postirradiation vaginal angiosarcoma treated with recombinant interleukin-2 therapy
  1. K. TAKEUCHI*,
  2. M. DEGUCHI*,
  3. S. HAMANA*,
  4. S. MOTOYAMA*,
  5. S. KITAZAWA and
  6. T. MARUO*
  1. *Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, Japan
  2. Division of Molecular Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
  1. Address correspondence and reprint requests to: Kyousuke Takeuchi, MD, Department of Obstetrics and Gynecology, Kobe University Graduate School of medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Email: kyousuket{at}


Angiosarcoma of the vagina is an extremely rare neoplasm and is characterized by frequent recurrence and early metastatic spread. Although previous reports emphasized the poor prognosis of this disease, effective treatment strategies have not been adequately stated. We report a case of angiosarcoma of the vagina, in which the diagnosis was made 9 years after intrapelvic irradiation, and recombinant interleukin-2 (rIL-2) therapy could be effective to suppress the development of distant metastasis. We recommend rIL-2 therapy in combination with irradiation as a palliative therapeutic option for vaginal angiosarcoma when the tumor is inoperable or the patient refuses to undergo surgery. Although vaginal angiosarcoma is an extremely rare condition, its possibility should be borne in mind when finding a vaginal mass in a previously irradiated patient.

  • angiosarcoma
  • interleukin-2
  • irradiation
  • vagina

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.